PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Hannah L BuckleyFiona J CollinsonGemma AinsworthHeather PoadLouise FlanaganEszter KatonaHelen C HowardGeraldine MurdenRosamonde E BanksJoanne BrownGalina VelikovaTom WaddellKate FifePaul D NathanJames LarkinThomas PowlesSarah R BrownNaveen S VasudevPublished in: BMC cancer (2019)
At the time of submission, PRISM is open to recruitment and data collection is ongoing.